COVID-19 and Rheumatology

COVID-19 and Rheumatology

Disclosures: The researchers report funding Novartis. Caricchio additionally reports grants from Janssen and personal fees from Janssen, GlaxoSmithKline, Bristol Myers Squibb, Eli Lilly & Co.and Siemens. Please see the study for all other authors’ relevant financial disclosures.
July 20, 2021
2 min read
Save

Canakinumab fails to improve survival odds without ventilation in severe COVID-19

Disclosures: The researchers report funding Novartis. Caricchio additionally reports grants from Janssen and personal fees from Janssen, GlaxoSmithKline, Bristol Myers Squibb, Eli Lilly & Co.and Siemens. Please see the study for all other authors’ relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Canakinumab fails to significantly increase the likelihood of survival without accompanying invasive mechanical ventilation, compared with placebo, in patients with severe COVID-19, according to data published in JAMA.

“IL-1 is an upstream proinflammatory cytokine that is involved in the pathogenesis of a variety of autoinflammatory conditions and induces the production of secondary inflammatory mediators, including IL-6,” Roberto Caricchio, MD, of the Lewis Katz School of Medicine at Temple University, in Philadelphia, and colleagues wrote. “In vitro experiments have shown that infection with SARS-CoV-2 triggers activation of the inflammasome and the maturation and release of IL-1.”

Canakinumab fails to significantly increase the likelihood of survival without invasive mechanical ventilation, compared with placebo, in patients with severe COVID-19, according to data derived from Caricchio R, et al. JAMA. 2021;doi:10.1001/jama.2021.9508.

“Postmortem examination of lungs of patients who died of COVID-19 pneumonia have revealed intense inflammasome formation,” they added. “Immuno-profile studies have shown that IL-1 is one of the inflammatory cytokines that defines the ‘core COVID-19 signature’.”

To examine the efficacy of the IL-1 inhibitor canakinumab (Ilaris, Novartis), in patients who are hospitalized with severe COVID-19, Caricchio and colleagues conducted the CAN-COVID trial. According to the researchers, this randomized, double-blind, placebo-controlled phase 3 study included 454 participants with COVID-19 pneumonia from 39 hospitals in Europe and the United States.

Roberto Caricchio

Patients additionally demonstrated hypoxia, not requiring invasive mechanical ventilation, and systemic hyperinflammation defined by increased blood concentrations of C-reactive protein or ferritin. They were enrolled between April 30, 2020, and Aug. 17, 2020, with the last assessment of the primary endpoint on Sept. 22, 2020.

Participants were randomized 1:1 to receive either a single intravenous infusion of canakinumab, at a dose of 450 mg for those weighing less than 60 kg, 600 mg for those 60-80 kg, and 750 mg for those above 80 kg, or placebo. The primary outcome was survival without invasive mechanical ventilation from day 3 to day 29. Secondary outcomes included mortality related to COVID-19, as well as biomarker measurements of systemic hyperinflammation and safety.

According to the researchers, 88.8% of participants in the canakinumab group survived without requiring ventilation, compared with 85.7% of those who received placebo, with a rate difference of 3.1% (95% CI, –3.1% to 9.3%) and an odds ratio of 1.39 (95% CI, 0.76-2.54). Meanwhile, mortality related to COVID-19 occurred in 4.9% of participants in the canakinumab group, compared with 7.2% in the placebo group, with a rate difference of –2.3% (95% CI, –6.7% to 2.2%) and an odds ratio of 0.67 (95% CI, 0.3-1.5).

Serious adverse events were observed in 16% of those treated with canakinumab, compared with 20.6% in the placebo group.

“In this multicenter, double-blind, placebo-controlled, randomized clinical trial conducted at 39 hospitals in Europe and the United States, the IL-1 inhibitor canakinumab did not significantly increase the likelihood of survival without [invasive mechanical ventilation] among patients hospitalized with severe COVID-19,” Caricchio and colleagues wrote. “These findings were also consistent for the secondary outcome of COVID19–related mortality.”